CADL NASDAQ
Candel Therapeutics, Inc.
1W: -4.5%
1M: -26.3%
3M: -12.2%
YTD: +51.6%
1Y: +52.8%
3Y: +816.7%
5Y: -16.4%
$8.25
+0.46 (+5.91%)
Weekly Expected Move ±6.7%
$7
$7
$8
$9
$9
Credit Risk of going bust: higher than 54% of companies Debt: 7.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.09 (down 99%), Candel Therapeutics, Inc. would be worth roughly what it owes.
Total debt $49.5M against a stock market value of $631.3M.
Distance to default 4.70 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $23.9M (short-term plus half of long-term), stock volatility 69.0%; Altman Z'' 0.59. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.09 (down 99%), Candel Therapeutics, Inc. would be worth roughly what it owes.
Total debt $49.5M against a stock market value of $631.3M.
Distance to default 4.70 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $23.9M (short-term plus half of long-term), stock volatility 69.0%; Altman Z'' 0.59. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$631.3M
52W Range4.35-14
Volume928,433
Avg Volume1,369,696
Beta-0.47
Dividend—
Analyst Ratings
Company Info
CEOPaul-Peter Tak
Employees55
SectorHealthcare
IndustryBiotechnology
IPO Date2021-07-27
Websitecandeltx.com
117 Kendrick Street
Needham, MA 02494
US
Needham, MA 02494
US
617 916 5445
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
Latest News
Candel Therapeutics, Inc. (NASDAQ:CADL) Stock Has Consensus Price Target of $20.14 According to Brokerages
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
Candel upgraded at BofA on prostate cancer gene therapy
10 small-cap healthcare stocks with the strongest momentum grades
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Loggia Nicoletta | A-Award | 380 | $10.44 | 2026-09-30 |
| PAPA JOSEPH C | A-Award | 1,325 | $10.44 | 2026-09-30 |
| Manning Paul B | A-Award | 2,189 | $10.44 | 2026-09-30 |
| Tak Paul Peter | S-Sale | 59,379 | $10.46 | 2026-09-11 |
| Tak Paul Peter | S-Sale | 220,866 | $11.50 | 2026-09-10 |